Home > Uncategorized > PROSPECT Trial Revisited

PROSPECT Trial Revisited

The DAPT trial and PEGASUS-TIMI 54 trial have provided evidence of benefit (reduction in ischemic events) for longer duration of antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention. This post revisits the PROSPECT trial. The importance of non-culprit lesion events and risk factors for recurrent events will be presented below.


  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: